CombiMatrix Corp (CBMX)

2.95
NASDAQ : Health Care
Prev Close 2.85
Day Low/High 2.75 / 2.95
52 Wk Low/High 2.15 / 14.70
Avg Volume 250.90K
Exchange NASDAQ
Shares Outstanding 2.50M
Market Cap 7.13M
EPS -9.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CombiMatrix Notes Decision By Health Care Service Corporation To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Notes Decision By Health Care Service Corporation To Reimburse For Recurrent Pregnancy Loss Testing

Trend continues by health providers to cover chromosomal microarray testing for recurrent pregnancy loss

CombiMatrix Announces Distribution Agreement With Universal Diagnostic Laboratories For Miscarriage Analysis Testing

CombiMatrix Announces Distribution Agreement With Universal Diagnostic Laboratories For Miscarriage Analysis Testing

Agreement expands access to CombiMatrix's test for women in the state of California

CombiMatrix Study Published In Genetics In Medicine Establishes The Superior Diagnostic Value Of Microarray Analysis Over Karyotyping For Recurrent Pregnancy Loss Testing

CombiMatrix Study Published In Genetics In Medicine Establishes The Superior Diagnostic Value Of Microarray Analysis Over Karyotyping For Recurrent Pregnancy Loss Testing

Data further validates CombiMatrix's microarray testing for miscarriage analysis and supports position as commercial and scientific leader in the $300 million annual U.S. market

CombiMatrix Launches Next Generation Sequencing For Pre-Implementation Genetic Screening

CombiMatrix Launches Next Generation Sequencing For Pre-Implementation Genetic Screening

High sensitivity and specificity PGS testing by Next Generation Sequencing supports healthy pregnancies and builds on prenatal diagnostics portfolio

CombiMatrix Comments On Additional Medical Policy Revisions To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Comments On Additional Medical Policy Revisions To Reimburse For Recurrent Pregnancy Loss Testing

Genetic testing now categorized by six additional health plans as medically necessary for the evaluation of pregnancy loss in specific cases

CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies To Reimburse For Recurrent Pregnancy Loss Testing

Seven health plans in 2016 announce coverage for chromosomal microarray testing for recurrent pregnancy loss

CombiMatrix Provides Strategic Update

CombiMatrix Provides Strategic Update

CombiMatrix Comments On Medical Policy Revisions By Cigna Health And Three BCBS Health Plans To Reimburse For Recurrent Pregnancy Loss Testing

CombiMatrix Comments On Medical Policy Revisions By Cigna Health And Three BCBS Health Plans To Reimburse For Recurrent Pregnancy Loss Testing

Six plans over the past 10 weeks announce coverage for chromosomal microarray testing for recurrent pregnancy loss

ACOG And SMFM Update Practice Bulletins Recommending Prenatal Genetic Assessment For All Pregnant Women Regardless Of Age Or Other Risk Factors

ACOG And SMFM Update Practice Bulletins Recommending Prenatal Genetic Assessment For All Pregnant Women Regardless Of Age Or Other Risk Factors

Associations Endorse Chromosomal Microarray Analysis for Confirmatory Testing

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

CombiMatrix Migrates Miscarriage Analysis Microarray Testing To Newer Scanning Panel

CombiMatrix Migrates Miscarriage Analysis Microarray Testing To Newer Scanning Panel

Illumina CytoSNP-12 Features High-Quality Test Results at Reduced Cost per Array

CombiMatrix Study Published In Genetics In Medicine

CombiMatrix Study Published In Genetics In Medicine

Study Supports Follow-up Diagnostic Testing to Confirm Positive Results From Non-invasive Prenatal Testing